home / stock / autl / autl quote
Last: | $3.45 |
---|---|
Change Percent: | -0.29% |
Open: | $3.5 |
Close: | $3.45 |
High: | $3.52 |
Low: | $3.29 |
Volume: | 1,575,755 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.45 | $3.5 | $3.45 | $3.52 | $3.29 | 1,575,755 | 07-05-2024 |
$3.49 | $3.41 | $3.49 | $3.505 | $3.38 | 641,766 | 07-04-2024 |
$3.49 | $3.41 | $3.49 | $3.505 | $3.38 | 641,766 | 07-03-2024 |
$3.38 | $3.44 | $3.38 | $3.47 | $3.31 | 1,546,816 | 07-02-2024 |
$3.47 | $3.45 | $3.47 | $3.5503 | $3.37 | 638,111 | 07-01-2024 |
$3.48 | $3.33 | $3.48 | $3.555 | $3.125 | 2,450,789 | 06-28-2024 |
$3.33 | $3.38 | $3.33 | $3.435 | $3.23 | 903,992 | 06-27-2024 |
$3.36 | $3.48 | $3.36 | $3.57 | $3.345 | 1,031,119 | 06-26-2024 |
$3.48 | $3.73 | $3.48 | $3.73 | $3.48 | 1,257,447 | 06-25-2024 |
$3.72 | $3.85 | $3.72 | $3.9 | $3.7 | 1,005,890 | 06-24-2024 |
$3.83 | $3.91 | $3.83 | $4.025 | $3.82 | 2,775,049 | 06-21-2024 |
$3.86 | $3.96 | $3.86 | $4.09 | $3.82 | 1,423,955 | 06-20-2024 |
$3.9 | $4.3 | $3.9 | $4.33 | $3.87 | 1,845,523 | 06-19-2024 |
$3.9 | $4.3 | $3.9 | $4.33 | $3.87 | 1,845,523 | 06-18-2024 |
$4.31 | $4.5 | $4.31 | $4.775 | $4.22 | 1,816,657 | 06-17-2024 |
$4.5 | $4.49 | $4.5 | $4.55 | $4.32 | 1,694,667 | 06-14-2024 |
$4.53 | $4.33 | $4.53 | $4.56 | $4.23 | 1,383,646 | 06-13-2024 |
$4.34 | $4.4 | $4.34 | $4.43 | $4.07 | 2,010,850 | 06-12-2024 |
$4.31 | $4.04 | $4.31 | $4.33 | $3.97 | 1,034,626 | 06-11-2024 |
$4.05 | $3.98 | $4.05 | $4.08 | $3.895 | 1,461,172 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Autolus Therapeutics plc Company Name:
AUTL Stock Symbol:
NASDAQ Market:
Autolus Therapeutics plc Website:
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated wi...
Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations at ASCO and EHA Two patients enrolled in Phase 1 Systemic Lupus Erythematosus (SLE) trial; study on track for initial data end of 2024 Market Authorization Application (M...